1. Home
  2. GPRO vs CINGW Comparison

GPRO vs CINGW Comparison

Compare GPRO & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPRO
  • CINGW
  • Stock Information
  • Founded
  • GPRO 2004
  • CINGW N/A
  • Country
  • GPRO United States
  • CINGW United States
  • Employees
  • GPRO N/A
  • CINGW 13
  • Industry
  • GPRO Industrial Machinery/Components
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPRO Consumer Discretionary
  • CINGW Health Care
  • Exchange
  • GPRO Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • GPRO N/A
  • CINGW N/A
  • IPO Year
  • GPRO 2014
  • CINGW 2021
  • Fundamental
  • Price
  • GPRO $1.30
  • CINGW $0.07
  • Analyst Decision
  • GPRO Sell
  • CINGW
  • Analyst Count
  • GPRO 2
  • CINGW 0
  • Target Price
  • GPRO $2.25
  • CINGW N/A
  • AVG Volume (30 Days)
  • GPRO 1.0M
  • CINGW N/A
  • Earning Date
  • GPRO 11-05-2024
  • CINGW N/A
  • Dividend Yield
  • GPRO N/A
  • CINGW N/A
  • EPS Growth
  • GPRO N/A
  • CINGW N/A
  • EPS
  • GPRO N/A
  • CINGW N/A
  • Revenue
  • GPRO $931,412,000.00
  • CINGW N/A
  • Revenue This Year
  • GPRO N/A
  • CINGW N/A
  • Revenue Next Year
  • GPRO $6.42
  • CINGW N/A
  • P/E Ratio
  • GPRO N/A
  • CINGW N/A
  • Revenue Growth
  • GPRO N/A
  • CINGW N/A
  • 52 Week Low
  • GPRO $1.16
  • CINGW N/A
  • 52 Week High
  • GPRO $3.80
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • GPRO 47.99
  • CINGW N/A
  • Support Level
  • GPRO $1.27
  • CINGW N/A
  • Resistance Level
  • GPRO $1.38
  • CINGW N/A
  • Average True Range (ATR)
  • GPRO 0.05
  • CINGW 0.00
  • MACD
  • GPRO -0.00
  • CINGW 0.00
  • Stochastic Oscillator
  • GPRO 20.00
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: